English
Chinese (Simplified)
About Us
INmuneBio
INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.
Products
INKmune™
INKmune is a biologic delivery system that allows us to deliver the missing S1 (priming signal) to the patient’s resting NK cells. INKmune is delivered by a simple IV infusion.
Products
INB03
INB03 is a checkpoint inhibitor that targets myeloid-derived suppressor cells (MDSC) in the tumor microenvironment that produce an immunosuppressive shield that prevents the patient’s immune system from attacking the cancer.
Stay Tuned
Latest News
- Feb 11, 2019 INmune Bio Awarded a $1 Million Grant for the Development of XPro1595 for the treatment of Alzheimer’s Disease
- Feb 06, 2019 INmune Bio to Present at BIO CEO & Investor Conference
- Feb 04, 2019 INmune Bio Inc. Announces Closing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol “INMB”
| Have a Question? 858 964 3720 |
| Email Us dmoss@inmunebio.com |
| Opening Hours M - F 8am to 5pm PST |